RSV Vaccines Highly Effective in Reducing Hospitalizations and Deaths for Seniors
Respiratory syncytial virus vaccines developed by GlaxoSmithKline and Pfizer reduce the risk of RSV-related hospitalization or death by approximately 80% in adults aged 65 and older, according to a U.S. Food and Drug Administration study published Sept. 18 in JAMA Network Open covering 14.8 million Medicare beneficiaries.
When two new vaccines targeting respiratory syncytial virus entered the American healthcare market in 2023, public health officials faced an immediate clinical question. Clinical trials had demonstrated high efficacy, but researchers needed to verify if those controlled findings would translate to older populations living across diverse U.S. communities. The original trials took place during the later phases of the COVID-19 pandemic when circulating RSV levels dropped significantly below historical averages. That unique timing left some clinical investigators questioning whether real-world potency would match initial data.
“There was a little concern that maybe these vaccines will not turn out to be quite as potent as they appeared,” says Dr. Edward Walsh, a professor of medicine at the University of Rochester, reflecting on the initial rollout phase.
Real-World Data Confirms Clinical Trial Efficacy
The new JAMA Network Open study evaluated the complete U.S. population over the age of 65 enrolled in Medicare, representing a sample size vastly greater than earlier post-market evaluations. According to the findings, both the GlaxoSmithKline and Pfizer formulations performed similarly and mirrored the high efficacy demonstrated in pre-approval clinical trials. The data shows an approximate 80% reduction in severe outcomes, including hospital admissions and mortality tied to the virus.
Researchers examined demographic factors during the evaluation. Recipients of the RSV shots tended to live in more affluent areas and showed higher baseline rates of receiving annual influenza and COVID-19 immunizations. To determine whether healthcare access alone drove the survival gap, investigators performed an adjusted analysis. The high protective efficacy of the RSV vaccine remained constant even after accounting for access disparities. “That was nice to see, that the data really was identical,” Walsh notes regarding the adjusted findings.
Real-world evidence now confirms that the current generation of RSV vaccines successfully safeguards older adults against severe illness.